Literature DB >> 3153063

Renal disease and vasculitis.

J S Cameron1.   

Abstract

Vasculitis is rare in childhood, apart from Henoch-Schönlein purpura, and paediatric nephrologists see few cases of Wegener's granuloma or microscopic polyarteritis. In contrast, this pattern is reversed in adults. Recently much information about the presentation and longer-term course of both these conditions has been described in adults, and more aggressive treatment of severe cases with renal failure has improved the outlook from a 5-year survival of about 5%-80% or more. In parallel, it has become evident that the abundant immune complexes in the circulation of patients with vasculitis may play little or no role in the pathogenesis of the vasculitic lesions. Current interest centres both on the possible role of cell-mediated immunity and the recent finding of antibodies which react with antigens in the cytoplasm of leucocytes. These antibodies seem to be of clinical use in defining patients with vasculitis, especially when only the kidney is involved at a clinical level. The nature of this leucocyte antigen (or antigens) and the possible role of antibodies directed against them in the pathogenesis of the disease are subjects of current work in many laboratories.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3153063     DOI: 10.1007/bf00853446

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  47 in total

1.  Anti-neutrophil cytoplasm antibodies 1988.

Authors:  N Rasmussen; A Wiik; M Høier-Madsen; N Borregaard; F van der Woude
Journal:  Lancet       Date:  1988-03-26       Impact factor: 79.321

2.  Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis.

Authors:  C O Savage; C G Winearls; S Jones; P D Marshall; C M Lockwood
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

3.  Immunopathological studies of polyarteritis nodosa and Wegener's granulomatosis: a report of 43 patients with 51 renal biopsies.

Authors:  P Ronco; P Verroust; F Mignon; O Kourilsky; P Vanhille; A Meyrier; J P Mery; L Morel-Maroger
Journal:  Q J Med       Date:  1983

4.  Polyarteritis nodosa in childhood a clinical pathologic study.

Authors:  R E Ettlinger; A M Nelson; E C Burke; J T Lie
Journal:  Arthritis Rheum       Date:  1979-08

5.  Peculiar glomerular lesions in Takayasu's arteritis.

Authors:  M Yoshimura; H Kida; Y Saito; H Yokoyama; N Tomosugi; T Abe; N Hattori
Journal:  Clin Nephrol       Date:  1985-09       Impact factor: 0.975

6.  Idiopathic microscopic polyarteritis nodosa: ultrastructural observations on the renal vascular and glomerular lesions.

Authors:  V D'Agati; P Chander; M Nash; R Mancilla-Jimenez
Journal:  Am J Kidney Dis       Date:  1986-01       Impact factor: 8.860

7.  Improved prognosis of renal microscopic polyarteritis in recent years.

Authors:  G Fuiano; J S Cameron; M Raftery; B H Hartley; D G Williams; C S Ogg
Journal:  Nephrol Dial Transplant       Date:  1988       Impact factor: 5.992

8.  Intraglomerular T cells and monocytes in nephritis: study with monoclonal antibodies.

Authors:  F E Nolasco; J S Cameron; B Hartley; A Coelho; G Hildreth; R Reuben
Journal:  Kidney Int       Date:  1987-05       Impact factor: 10.612

9.  The role of vascular smooth muscle cells in experimental autoimmune vasculitis. I. The initiation of delayed type hypersensitivity angiitis.

Authors:  C F Moyer; C L Reinisch
Journal:  Am J Pathol       Date:  1984-12       Impact factor: 4.307

10.  Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis.

Authors:  I J ten Berge; J M Wilmink; C J Meyer; J Surachno; K H ten Veen; T G Balk; P T Schellekens
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

View more
  1 in total

1.  The absence of anti-neutrophil cytoplasmic antibodies in patients with Henoch-Schönlein purpura.

Authors:  W L Robson; A K Leung; R C Woodman
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.